UPSTREAM BIO, INC. Operating Income
UPSTREAM BIO, INC. (UPB) reported Operating Income of -$42.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- UPSTREAM BIO, INC. operating income (loss) for the quarter ending 2026-06-30 was -$42.37M.
- UPSTREAM BIO, INC. operating income (loss) for the quarter ending 2026-03-31 was -$43.62M.
- UPSTREAM BIO, INC. operating income (loss) for the quarter ending 2025-12-31 was -$46.17M.
- UPSTREAM BIO, INC. operating income (loss) for the quarter ending 2025-09-30 was -$37.83M.
- UPSTREAM BIO, INC. operating income (loss) for fiscal 2025 was -$160.36M.
- UPSTREAM BIO, INC. operating income (loss) for fiscal 2024 was -$77.76M.
- UPSTREAM BIO, INC. operating income (loss) for fiscal 2023 was -$40.11M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$42.37M 10-Q · filed 2026-08-11 | -$85.98M 10-Q · filed 2026-08-11 | -$132.15M derived: sum of 3 quarters · filed 2026-08-11 | -$169.98M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$43.62M 10-Q · filed 2026-05-13 | -$89.78M derived: sum of 2 quarters · filed 2026-05-13 | -$127.62M derived: sum of 3 quarters · filed 2026-05-13 | -$171.96M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$46.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$84.00M derived: sum of 2 quarters · filed 2026-03-26 | -$128.35M derived: sum of 3 quarters · filed 2026-08-11 | -$160.36M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$37.83M 10-Q · filed 2025-11-05 | -$82.18M derived: sum of 2 quarters · filed 2026-08-11 | -$114.19M 10-Q · filed 2025-11-05 | -$140.51M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$44.35M 10-Q · filed 2026-08-11 | -$76.36M 10-Q · filed 2026-08-11 | -$102.68M derived: sum of 3 quarters · filed 2026-08-11 | -$121.57M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$32.01M 10-Q · filed 2026-05-13 | -$58.33M derived: sum of 2 quarters · filed 2026-05-13 | -$77.22M derived: sum of 3 quarters · filed 2026-05-13 | -$94.76M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$26.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$45.21M derived: sum of 2 quarters · filed 2026-03-26 | -$62.75M derived: sum of 3 quarters · filed 2026-03-26 | -$77.76M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$18.89M 10-Q · filed 2025-11-05 | -$36.43M derived: sum of 2 quarters · filed 2025-11-05 | -$51.45M 10-Q · filed 2025-11-05 | -$65.78M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$17.54M 10-Q · filed 2025-08-06 | -$32.55M 10-Q · filed 2025-08-06 | -$46.88M derived: sum of 3 quarters · filed 2025-08-06 | -$56.27M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$15.01M 10-Q · filed 2025-05-06 | -$29.34M derived: sum of 2 quarters · filed 2025-05-06 | -$38.73M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | -$14.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$23.72M derived: sum of 2 quarters · filed 2025-03-12 | -$40.11M 10-K · filed 2025-03-12 | |
| 2023-09-30 | -$9.39M 10-Q · filed 2024-11-07 | -$25.78M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |